BIOVIE INC.
BIVI · XNASCIK 1580149fmd_159PRVKA1Q3R3E3SXZJEQDZSPZManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2012 to Sep 30, 2026, 54 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | 0 | 0 | 1 | 1 | 3 | 17 | 33 | 23 | 9 | 14 |
| Selling, general and administrative | 0 | 2 | 1 | 1 | 5 | 10 | 12 | 9 | 9 | – |
| Total operating expenses | 2 | 2 | 2 | 3 | 138 | 27 | 45 | 32 | 18 | 23 |
| Compensation and benefits | 0 | 0 | – | – | – | – | – | – | – | – |
| Operating income | (2) | (2) | (2) | (3) | (138) | (27) | (45) | (32) | (18) | (23) |
| Interest expense | – | 0 | 0 | 5 | 1 | 2 | 4 | 3 | 0 | 0 |
| Other non-operating income (expense) | – | – | – | – | – | – | (5) | 0 | 1 | 1 |
| Net income | (1) | (2) | (2) | (17) | (130) | (26) | (50) | (32) | (18) | (22) |
| Net income to common shareholders | – | – | – | – | – | (26) | (50) | (33) | – | – |